EP3773528A4 - Hemp extract for treatment of pain in animals - Google Patents

Hemp extract for treatment of pain in animals Download PDF

Info

Publication number
EP3773528A4
EP3773528A4 EP19785569.5A EP19785569A EP3773528A4 EP 3773528 A4 EP3773528 A4 EP 3773528A4 EP 19785569 A EP19785569 A EP 19785569A EP 3773528 A4 EP3773528 A4 EP 3773528A4
Authority
EP
European Patent Office
Prior art keywords
pain
animals
treatment
hemp extract
hemp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19785569.5A
Other languages
German (de)
French (fr)
Other versions
EP3773528A2 (en
EP3773528B1 (en
Inventor
Amanda HOWLAND
Christian Kjaer
Michael Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Portland Technology Holdings LLC
Original Assignee
Ellevet Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ellevet Sciences filed Critical Ellevet Sciences
Publication of EP3773528A2 publication Critical patent/EP3773528A2/en
Publication of EP3773528A4 publication Critical patent/EP3773528A4/en
Application granted granted Critical
Publication of EP3773528B1 publication Critical patent/EP3773528B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
EP19785569.5A 2018-04-09 2019-04-09 Hemp extract for treatment of pain in animals Active EP3773528B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862655170P 2018-04-09 2018-04-09
PCT/US2019/026631 WO2019199861A2 (en) 2018-04-09 2019-04-09 Hemp extract for treatment of pain in animals

Publications (3)

Publication Number Publication Date
EP3773528A2 EP3773528A2 (en) 2021-02-17
EP3773528A4 true EP3773528A4 (en) 2022-01-05
EP3773528B1 EP3773528B1 (en) 2024-01-10

Family

ID=68163314

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19785569.5A Active EP3773528B1 (en) 2018-04-09 2019-04-09 Hemp extract for treatment of pain in animals

Country Status (10)

Country Link
US (2) US20230110830A1 (en)
EP (1) EP3773528B1 (en)
JP (1) JP2021521277A (en)
CN (1) CN112969452A (en)
AU (1) AU2019251357B2 (en)
BR (1) BR112020020850A2 (en)
CA (1) CA3096842A1 (en)
MX (1) MX2020010603A (en)
SG (1) SG11202010006UA (en)
WO (1) WO2019199861A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021532171A (en) * 2018-07-02 2021-11-25 コンパニオン サイエンシズ リミテッド ライアビリティ カンパニー Combination composition of cannabidiol
US11484487B1 (en) * 2018-07-23 2022-11-01 Robell Research, Inc. Gingivitis gum serum
AU2020298550A1 (en) * 2019-07-02 2022-02-17 Portland Technology Holdings Llc Hemp extract for treatment of pain, cancer and epilepsy in animals
CN111956664A (en) * 2019-12-03 2020-11-20 云南汉盟制药有限公司 Composition for pets and application thereof
WO2021127749A1 (en) * 2019-12-24 2021-07-01 Cannadol Pharmaceuticals Ltd Compositions comprising terpenes and their use in the treatment or alleviation of pain or anxiety
US20230091336A1 (en) * 2020-02-25 2023-03-23 The Queen's Medical Center Cannabinoid compositions
WO2021226099A1 (en) * 2020-05-04 2021-11-11 Agronomed Management, Llc Topical anti-inflammatory cannabinoid compositions
JP2023529476A (en) * 2020-06-12 2023-07-10 ゼリラ セラピューティクス オペレーションズ ピーティーワイ リミテッド Compositions and methods for treating chronic pain
US20220110888A1 (en) * 2020-10-09 2022-04-14 Charlotte's Web, Inc. Composition for the treatment of psoriasis
WO2023130160A1 (en) * 2022-01-10 2023-07-13 Dolce Cann Global Pty Ltd Compositions and methods for treating non-neurological disorders with combination products comprising a cannabinoid mixture rich in cannabidiolic acid (cbda).
WO2023130161A1 (en) * 2022-01-10 2023-07-13 Dolce Cann Global Pty Ltd Compositions and methods for treating non-neurological disorders with combination products comprising a cannabinoid mixture rich in cannabidiolic acid (cbda) along with an additional active agent
WO2023173060A1 (en) * 2022-03-10 2023-09-14 Portland Technology Holdings Llc Compositions comprising hemp extract and related treatment methods
WO2024082014A1 (en) * 2022-10-21 2024-04-25 Dolce Cann Global Pty Ltd Compositions comprising cannabidiolic acid and fatty acids
KR102524364B1 (en) * 2022-10-24 2023-04-24 전북대학교산학협력단 Composition for preventing or treating periodontitis comprising cannabidiol and taurine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072719A1 (en) * 2004-02-02 2005-08-11 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Medicinal acidic cannabinoids
WO2012144892A1 (en) * 2011-04-18 2012-10-26 Fytagoras B.V. Medical use for acidic cannabinoids

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10051427C1 (en) 2000-10-17 2002-06-13 Adam Mueller Process for the production of an extract containing tetrahydrocannabinol and cannabidiol from cannabis plant material and cannabis extracts
EP1482917B1 (en) 2002-02-01 2019-05-08 GW Pharma Limited Compositions comprising cannabidiolic acid for treatment of nausea, vomiting, emesis, motion sickness or like conditions
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
CN1840051B (en) * 2006-01-23 2013-08-28 北京因科瑞斯生物制品研究所 Pain-stopping gel with musk and its preparation method
US8481085B2 (en) 2006-06-15 2013-07-09 Gw Pharma Limited Pharmaceutical compositions comprising cannabigerol
GB2448535A (en) 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
GB2450493A (en) 2007-06-25 2008-12-31 Gw Pharma Ltd Cannabigerol for use in treatment of diseases benefiting from agonism of CB1 and CB2 cannabinoid receptors
EP2044935B1 (en) 2007-10-02 2011-01-05 Vivacell Biotechnology Espana S.L. A composition containing non-psychotropic cannabinoids for the treatment of inflammatory diseases
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
GB2494461A (en) 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
BR112014007603A2 (en) 2011-09-30 2017-06-13 Glaxosmithkline Llc cancer treatment methods
US9254272B2 (en) 2011-11-30 2016-02-09 Sutter West Bay Hospitals Resorcinol derivatives
US10350251B2 (en) * 2012-03-28 2019-07-16 Keith Gerald Freeman Medical compositions, methods of making and using those compositions, and kits including those compositions
US20140256692A1 (en) * 2013-03-07 2014-09-11 Nicholas Adam Brockman Composition and Method for Alleviation of Pain and Inflammation
GB2515312A (en) 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
WO2015025312A1 (en) * 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
CN105916492A (en) 2013-10-31 2016-08-31 全谱实验室有限公司 Terpene and cannabinoid formulations
CA2931486A1 (en) 2013-11-05 2015-05-14 Ardent Llc Sublingual cannabis dosage form and methods of making and using the same
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
US20160000843A1 (en) 2014-07-01 2016-01-07 MJAR Holdings, LLC High cannabidiol cannabis strains
AU2015308136B2 (en) 2014-08-25 2020-07-09 Teewinot Technologies Limited Apparatus and methods for the simultaneous production of cannabinoid compounds
EP3209312A1 (en) * 2014-10-21 2017-08-30 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
EP3226847A2 (en) 2014-12-04 2017-10-11 Servicio Andaluz De Salud Use of cannabinoids as ceramide-generating anticancer agents in tumors of the hematopoietic and lymphoid tissues
JP2018505912A (en) * 2014-12-12 2018-03-01 オーハイ エナジェティクス ピービーシー Microencapsulated cannabinoid composition
MX2017009846A (en) 2015-01-31 2018-04-11 Constance Therapeutics Inc Methods for preparation of cannabis oil extracts and compositions.
US20160228385A1 (en) * 2015-02-05 2016-08-11 Colorado Can Llc Purified cbd and cbda, and methods, compositions and products employing cbd or cbda
WO2016133824A1 (en) 2015-02-16 2016-08-25 Axim Biotechnologies, Inc. Cosmetic and topical compositions comprising cannabigerol
US20170266153A1 (en) 2015-02-27 2017-09-21 Ebbu, LLC Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
US10716766B2 (en) * 2015-03-02 2020-07-21 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
US20180116998A1 (en) 2015-05-13 2018-05-03 One World Cannabis Ltd Use of cannabis to treat fibromyalgia, methods and compositions thereof
WO2016189384A1 (en) 2015-05-28 2016-12-01 Tweed Inc. Cannabis plants having modified expression of thca synthase
WO2017013661A1 (en) * 2015-07-22 2017-01-26 Phytopharma International Ltd. Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby
US10064950B2 (en) 2015-07-24 2018-09-04 Shabana Naheed Medication dispensing system
GB2541191A (en) * 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2542797A (en) 2015-09-29 2017-04-05 Gw Pharma Ltd Use of cannabinoids in the treatment of inflammatory skin diseases
CA3006182A1 (en) * 2015-11-24 2017-06-01 Constance Therapeutics, Inc. Cannabis oil compositions and methods for preparation thereof
US9956174B1 (en) 2016-02-08 2018-05-01 Jeff Nordahl Packaged frozen cubes of cannabis juice purée with added decarboxylated cannabis material
GB2549277B (en) 2016-04-11 2021-02-17 Gw Res Ltd Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder
CA3020798A1 (en) 2016-04-12 2017-10-19 Scott SCHANEVILLE Ingestible films having substances from hemp or cannabis
EP3442515A4 (en) 2016-04-12 2019-12-04 Little Green Pharma Ltd Liposomal preparation and methods of treatment
LT6486B (en) * 2016-04-13 2018-01-10 UAB "SatiMed" The oleo gel composition and delivery system with active compounds from c. sativa and m. arvensis for reduction of inflamation and pain in deep tissues
CN106074465A (en) * 2016-06-14 2016-11-09 云南瑞酚生物科技有限公司 Cannabinol compounds application in preparation treatment gouty arthritis medicine
IL246790A0 (en) 2016-07-14 2016-09-29 Friedman Doron Self-emulsifying compositions of cannabinoids
KR102447510B1 (en) * 2016-08-03 2022-09-27 젤리라 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 Cannabis composition
BR112019003815A2 (en) 2016-08-29 2019-05-21 Canopy Growth Corporation water soluble compositions comprising purified cannabinoids
AU2017328499A1 (en) 2016-09-14 2019-04-04 Altria Client Services Llc Smoking device
IL248149B (en) * 2016-09-29 2020-03-31 Garti Nissim Dilutable formulations of cannbinoids and processes for their preparation
AU2018207955B2 (en) * 2017-01-14 2022-10-06 Herbolea Biotech S.R.L. Enzyme-assisted lipid-based extraction and stabilization of phyto-cannabinoids and terpens and products obtained thereof
AU2018239222A1 (en) * 2017-03-18 2019-09-26 Thomas A. Asquith Pet food including cannabidiolic acid
WO2018175796A1 (en) 2017-03-24 2018-09-27 STAUFF, Deidra Skin care compositions and methods
US11117852B2 (en) 2017-04-05 2021-09-14 University Of Mississippi Isolation of pure cannabinoids from Cannabis
KR20200019864A (en) 2017-05-08 2020-02-25 인메드 파마슈티컬스 인코포레이티드 Ocular Drug Delivery Formulations
EP3630063A2 (en) 2017-05-22 2020-04-08 GBS Global Biopharma, Inc. Myrcene-containing complex mixtures targeting trpv1
CA3068383A1 (en) 2017-06-28 2019-01-03 Buzzelet Development And Technologies Ltd. Terpene-enriched cannabinoid product for women health
ES2947367T3 (en) 2017-07-26 2023-08-07 Tgx Soft Chew Llc Non-starchy soft chew for veterinary applications
US10597348B1 (en) 2017-08-21 2020-03-24 Jeff Nordahl Infusing raw cannabinoids into food oil
US20190060250A1 (en) 2017-08-28 2019-02-28 Axim Biotechnologies, Inc. Method to treat psoriasis
US10272051B2 (en) 2017-08-28 2019-04-30 Axim Biotechnologies, Inc. Method to treat atopic dermatitis
US11484510B2 (en) 2017-08-28 2022-11-01 Apirx Pharmaceutical Usa, Llc Method to treat vitiligo
EP3449992A1 (en) 2017-09-04 2019-03-06 Bionorica Ethics GmbH Recovery of acidic cannabinoids from plant material
CN111212638A (en) 2017-09-08 2020-05-29 西卡恩治疗公司 Compositions comprising cannabinoids and spilanthol
US10654823B2 (en) 2017-09-09 2020-05-19 Scientific Holdings, Llc Transparent glassy cannabinoid compositions
CA3074510A1 (en) 2017-10-03 2019-04-11 The Regents Of The University Of Colorado Method for differentiating cannabis plant cultivars based on cannabinoid synthase paralogs
WO2019071302A1 (en) 2017-10-09 2019-04-18 The University Of Sydney Methods and compositions for treating or preventing seizures
US20200289459A1 (en) 2017-11-30 2020-09-17 Canopy Growth Corporation Liquid dosage forms, methods of making and use
US20200405685A1 (en) 2017-12-08 2020-12-31 Biotech Institute, Llc High cannabigerol cannabis plants, methods of producing and methods of using them
WO2019159170A1 (en) 2018-02-15 2019-08-22 Syqe Medical Ltd. Method and inhaler for providing two or more substances by inhalation
WO2019159176A1 (en) 2018-02-18 2019-08-22 Scicann Therapeutics Inc. Compositions and methods for treatment of neurodegenerative diseases
US20190297821A1 (en) 2018-03-28 2019-10-03 Jack Hempicine Llc Cross-hybridization of distinct homozygous cannabis plants to produce consistent early flowering seeds
WO2019195752A1 (en) 2018-04-05 2019-10-10 Canopy Holdings, LLC Hemp powder
WO2019210401A1 (en) 2018-05-01 2019-11-07 Willinsky Michael Novel anti-inflammatory, analgesic, anti-depressant cannabinoid and methods related to manufacture of same
WO2019227167A1 (en) 2018-06-01 2019-12-05 The University Of Sydney Compositions and treatments
CA3048539A1 (en) 2018-07-03 2020-01-03 Virgil Macaluso Methods of heating cannabis plant material
US20200015440A1 (en) 2018-07-12 2020-01-16 Jack Hempicine Llc Production of cannabis plants and seeds using a targeted allele
US20200015441A1 (en) 2018-07-12 2020-01-16 Jack Hempicine Llc Production of cannabis plants and seeds using a targeted allele
US20200288659A1 (en) 2018-07-12 2020-09-17 Jack Hempicine Llc Production of cannabis plants and seeds using a targeted allele
IL279824B2 (en) 2018-07-19 2023-10-01 Al& Am Pharmachem Ltd Process for purification of tetrahydrocannabinolic- and cannabidiolic acid from plant material extract
WO2020028875A1 (en) 2018-08-02 2020-02-06 DIVIOS, LLC (a California Limited Liability Company) Sunscreen composition comprising cannabis extracts
WO2020044118A1 (en) 2018-08-27 2020-03-05 Emerald Health Therapeutics Canada Inc. Improved cannabinoid bioavailability
WO2020044123A1 (en) 2018-08-27 2020-03-05 Emerald Health Therapeutics Canada Inc. Therapeutic combinations of boswellia extract and cannabinoids
CA3111979A1 (en) 2018-09-05 2020-03-12 Nemus Bioscience, Inc. Cannabinoids for the treatment of gram-positive infections including antibiotic-resistant bacterial strains
US10696646B2 (en) 2018-10-18 2020-06-30 Taba Ip, Llc Purification of cannabinoids from crude cannabis oil
WO2020084427A1 (en) 2018-10-23 2020-04-30 Radient Technologies Innovations Inc. Temperature control for active compound extraction
US20220015397A1 (en) 2018-12-10 2022-01-20 Natural Extraction Systems, LLC Compositions with novel cannabinoid and terpene profiles
WO2020121312A1 (en) 2018-12-12 2020-06-18 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Compositions and methods for the treatment of cutaneous t cell lymphoma (ctcl)
WO2020165902A1 (en) 2019-02-15 2020-08-20 Plantbiosis Ltd. Method for synthesis of cannabis products
NL2022616B1 (en) 2019-02-21 2020-09-18 Patrick Alexander Unger Cannabigerol and pharmaceutical compositions comprising cannabigerol for use in the treatment of insomnia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072719A1 (en) * 2004-02-02 2005-08-11 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Medicinal acidic cannabinoids
WO2012144892A1 (en) * 2011-04-18 2012-10-26 Fytagoras B.V. Medical use for acidic cannabinoids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SULAK DUSTIN ET AL: "The current status of artisanal cannabis for the treatment of epilepsy in the United States", EPILEPSY AND BEHAVIOR, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 70, 21 February 2017 (2017-02-21), pages 328 - 333, XP085033470, ISSN: 1525-5050, DOI: 10.1016/J.YEBEH.2016.12.032 *

Also Published As

Publication number Publication date
BR112020020850A2 (en) 2021-01-19
WO2019199861A3 (en) 2020-07-23
CA3096842A1 (en) 2019-10-17
CN112969452A (en) 2021-06-15
AU2019251357B2 (en) 2023-10-05
MX2020010603A (en) 2021-02-02
JP2021521277A (en) 2021-08-26
EP3773528A2 (en) 2021-02-17
EP3773528B1 (en) 2024-01-10
SG11202010006UA (en) 2020-11-27
US20220211790A1 (en) 2022-07-07
WO2019199861A2 (en) 2019-10-17
US11712456B2 (en) 2023-08-01
AU2019251357A1 (en) 2020-12-03
US20230110830A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
EP3773528A4 (en) Hemp extract for treatment of pain in animals
IL268138A (en) Combinations of cabozantinib and atezolizumab to treat cancer
EP3993780A4 (en) Hemp extract for treatment of pain, cancer and epilepsy in animals
EP3389532A4 (en) Apparatus and cosmetic method for cosmetic treatment of human mucosal tissue
EP3341392A4 (en) Compositions and methods for treatment of pain
EP3139939A4 (en) Compositions and methods for treating skin and mucous membrane diseases
AU2018295907A1 (en) Internal organ, injury and pain treatment
EP3538119A4 (en) Compositions and methods for treating skin diseases and maintaining healthy skin
IL272937A (en) Compositions and methods for the treatment of fibrotic diseases
EP3713583A4 (en) Methods and compositions for treatment of skin
EP3654961A4 (en) Methods and compositions for treatment of pain using capsaicin
EP3285767B8 (en) Treatment of pain
IL282473A (en) Cosmetic method and therapeutic use for fat reduction
EP3849591A4 (en) Methods and compositions for treating skin diseases
SG11201705524SA (en) Compositions and methods for the treatment of inflammation and pain
EP3691748A4 (en) Acetaminophen-pregabalin combinations and methods of treating pain
ZA202007320B (en) Compounds for pain treatment, compositions comprising same, and methods of using same
EP3458062A4 (en) Treatment of pain
EP3624722A4 (en) Methods and devices for treatment of subcutaneous fat
EP3468540A4 (en) Pharmaceutical compositions and methods for treatment of pain
IL280638A (en) Fat tissue treatment
EP3215124A4 (en) Composition and method for relieving pain and inflammation, treatment of erectile dysfunction, and treatment of acne
EP3758692A4 (en) Compositions and methods for treating pain
EP3873524A4 (en) Methods of treatment using anti-cd123 immunoconjugates
IL268111A (en) Methods of treating pain

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201022

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40045170

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20211202

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 29/00 20060101ALI20211126BHEP

Ipc: A61K 36/185 20060101ALI20211126BHEP

Ipc: A61K 36/00 20060101ALI20211126BHEP

Ipc: A61K 31/00 20060101ALI20211126BHEP

Ipc: A61K 31/05 20060101AFI20211126BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ELLEVET SCIENCES

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KJAER, CHRISTIAN

Inventor name: HOWLAND, AMANDA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220830

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PORTLAND TECHNOLOGY HOLDINGS LLC

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230522

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230803

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602019044936

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20240110